| NCT06752681 | To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2024-11-18 | 2028-12 | 2027-12 |
| NCT05566795 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | RECRUITING | PHASE3 | 2023-02-27 | 2030-03 | 2026-02 |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | TERMINATED | PHASE1 | 2022-05-02 | 2024-12-18 | 2024-12-18 |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | TERMINATED | PHASE2 | 2021-07-15 | 2024-07-08 | 2024-07-08 |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | RECRUITING | PHASE2 | 2021-04-22 | 2027-05-31 | 2027-05-31 |